Paper Review Records
All Paper Review Records
18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Generative AI-Designed Immunoglobulin Domain Antibodies (IgDAbs) Against the Fusion Protein as a Neutralizing Agent for Respiratory Syncytial Virus
Yenisetti Rajendra Prasad; Prakash Y. Khandave; Mihir Ratnaparkhe; Akash G. Kendre; Prasad V. Bharatam; Abhay H. PandeShow moreShow less
1. Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), India; 2. Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), India; 3. Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar (Mohali), IndiaShow moreShow less
Identity Testing of Biopharmaceuticals using Nano-Differential-Scanning-Fluorimetry
Elisabeth Fakler; Steffen Kiessig; Hanns-Christian Mahler; Andrea AllmendingerShow moreShow less
1. ten23 health AG, Basel, Switzerland; 2. Department of Pharmaceutics, Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg i. Br., GermanyShow moreShow less
Effects of Solvation and Noncovalent Interaction on Stabilizing the Molecular Structure of Etoricoxib
Anna A. Mololina; Konstantin V. Belov; Michael A. Krestyaninov; Hongxun Hao; Ilya A. KhodovShow moreShow less
1. G.A. Krestov Institute of Solution Chemistry, Russian Academy of Sciences, Ivanovo, Russia; 2. National Engineering Research Center of Industrial Crystallization Technology, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China; 3. N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, RussiaShow moreShow less
Formulation Development and Characterization of Ibrutinib-Loaded Liposomes with Molecular Dynamics Insights
Xiufang Cheng; Rijo John; Jasmin Monpara; Pardeep GuptaShow moreShow less
1. Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph’s University, Philadelphia, USAShow moreShow less
Effect of Oral Creatine Supplementation on Plasma, Central, and Peripheral Creatine Levels in Creatine Transporter Deficiency Mice
Naoto Tashiro; Ayaka Miyano; Mizuki Uchi; Tatsuki Uemura; Shingo Ito; Shoma Chikamatsu; Michihiko Sugimoto; Kimi Araki; Satohiro Nakao; Naomi Nakagata; Toru Takeo; Sumio OhtsukiShow moreShow less
1. Department of Pharmaceutical Microbiology, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; 2. Department of Pharmaceutical Microbiology, School of Pharmacy, Kumamoto University, Kumamoto, Japan; 3. Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; 4. Division of Developmental Genetics, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan; 5. Department of Genetics, School of Medicine, Hyogo Medical University, Hyogo, Japan; 6. Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; 7. Division of Reproductive Engineering, Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan; 8. Division of Reproductive Biotechnology and Innovation, Center for Animal Resources and Development, Kumamoto University, Kumamoto, JapanShow moreShow less
Time-Lapse Macro Imaging and LLM-Assisted Phenotypic Analysis of Release Dynamics in Nifedipine Controlled-Release Tablets
Ke Xu; Yixiang Yang; Yuling Chen; Xinzi Zhang; Yao Fu; Li DengShow moreShow less
1. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu, ChinaShow moreShow less
FAQ
How long does PHARMACEUTICAL RESEARCH take to review a manuscript?
As of 2026-11-19, CrushSCI has 18 complete review records for PHARMACEUTICAL RESEARCH. The fastest paper went from submission to acceptance in 54 days (Generative AI-Designed Immunoglobulin Domain Antibodies (IgDAbs) Against the Fusion Protein as a Neutralizing Agent for Respiratory Syncytial Virus, received 2026-08-17, accepted 2026-10-10); the slowest took 263 days. The average is 107 days and the median is 102.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
